| Literature DB >> 27801893 |
X Pham1,2, G Song3, S Lao4, L Goff1, H Zhu3, D Valle1,2, D Avramopoulos1,2.
Abstract
We previously reported a schizophrenia-associated polymorphic CT di-nucleotide repeat (DNR) at the 5'-untranslated repeat (UTR) of DPYSL2, which responds to mammalian target of Rapamycin (mTOR) signaling with allelic differences in reporter assays. Now using microarray analysis, we show that the DNR alleles interact differentially with specific proteins, including the mTOR-related protein HuD/ELAVL4. We confirm the differential binding to HuD and other known mTOR effectors by electrophoretic mobility shift assays. We edit HEK293 cells by CRISPR/Cas9 to carry the schizophrenia risk variant (13DNR) and observe a significant reduction of the corresponding CRMP2 isoform. These edited cells confirm the response to mTOR inhibitors and show a twofold shortening of the cellular projections. Transcriptome analysis of these modified cells by RNA-seq shows changes in 12.7% of expressed transcripts at a false discovery rate of 0.05. These transcripts are enriched in immunity-related genes, overlap significantly with those modified by the schizophrenia-associated gene, ZNF804A, and have a reverse expression signature from that seen with antipsychotic drugs. Our results support the functional importance of the DPYSL2 DNR and a role for mTOR signaling in schizophrenia.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27801893 PMCID: PMC5314117 DOI: 10.1038/tp.2016.204
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Figure 1Audiograph of electrophoretic mobility shift assay using labeled RNA probes for the 11 and 13DNR DNR alleles, and purified candidate-binding proteins. Results confirm binding for 4E-BP and elF4E and ELAVL4, seen as a shift up from the unlabeled oligos. In all cases, the binding was weaker, or eliminated for the 13 repeat risk allele. (The small upward shift of the 11DNR-unbound oligo band is likely due to a secondary structure, as it can be reduced or eliminated with heat treatment. See Supplementary Materials.) DNR, di-nucleotide repeat.
Figure 2(a) Western blots of targeted clones show significant differences in collapsin response mediator protein B2 (CRMP2B) levels (64 kDa) between the two isogenic cell groups. (b) In the presence of 30 nM Rapamycin, CRMPZB is reduced for both cell groups, but most dramatically in the 13PNR cells. (c) Quantification of western blots using the ImageJ software. *P<0.001; **P<2 × I0−5. DNR, di-nucleotide repeat.
Figure 3(a) Representative images of CRISPR-edited cells show morphological differences between the 11 and 13DNR cell groups. Cells stained tor wheat germ agglutinin (green) and nuclei (blue). (b) Quantification of projection lengths between the two isogenic cell groups confirms a significant difference, with the 13DNR risk allele showing shorter projections. DNR, di-nucleotide repeat.
Figure 4Dendrograms based on all genes. C1 is 13DNR and C2 is 11DNR. (a) Two 11DNR samples (C2_5 and C2_6) cluster together and separate early from all other samples, which together with the increased variance in the group, suggest that they are outliers. (b) After removing the outliers, the variance was restored; the first branching of the dendogram now separates the four 13DNR (C1) in one group and six 11DNR (C2) in the the other. Note that the numbering of the cell lines has now changed—C2_5 corresponds to previously C2_7. DNR, di-nucleotide repeat.
Gene ontology analysis using PANTHER bioinformatics
| P | P | |||
|---|---|---|---|---|
| Macrophage activation | 3.6 | 6.43 × 10−3 | — | — |
| Immune system process | 2.04 | 2.58 × 10−7 | — | — |
| Response to stimulus | 1.54 | 1.47 × 10−3 | — | — |
| mRNA splicing via splicesosome | — | 2.71 | 3.39 × 10−4 | |
| mRNA processing | — | 2.31 | 8.80 × 10−4 | |
| Nucleobase-containing cmpd metabolic process | — | 1.28 | 6.50 × 10−3 | |
| Metabol ic process | — | — | 1.15 | 6.49 × 10−3 |
| Extracellular matrix structural constituent | 4.24 | 6.55 X10−3 | — | — |
| Structural molecule activity | 1.74 | 2.22 × 10−4 | — | — |
| Receptor activity | 1.65 | 7.91 × 10−3 | — | — |
| RNA helicase activity | — | — | 4.12 | 1.28 × 10−4 |
| Translation initiation factor activity | — | — | 3.15 | 4.66 × 10−3 |
| mRNA binding | — | — | 2.88 | 1.04 × 10−3 |
| Helicase activity | — | — | 2.78 | 9.58 × 10−3 |
| Translation regulator activity | — | — | 2.78 | 9.58 × 10−3 |
| Nucleic acid binding | — | — | 2.72 | 8.76 × 10−3 |
| RNA binding | — | — | 2.58 | 5.25 × 10−10 |
| Extracellular matrix | — | 2.56 | 5.25 × 10−3 | |
| Extracellular region | 2.43 | 1.56 × 10−5 | ||